Nasdaq:RLMD
RELMADA THERAPEUTICS, INC.
A clinical-stage biotech firm advancing novel therapies for neurological conditions with a focus on epilepsy, stroke, and pain management.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock if they believe in the transformative potential of the company's neurological drug pipeline and its unique technology platform. The current asset base of $45.8M against liabilities of only $10.3M suggests a solvent balance sheet capable of supporting development until key data readouts.
Bear Case
The absence of any revenue stream combined with a massive accumulated deficit of nearly $641M presents an extreme risk profile for equity investors. With operating expenses exceeding $83M annually and no commercial products, the company is highly dependent on future fundraising or successful stock-based financing.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, including epilepsy, stroke, and chronic pain. Operating primarily in the United States and international markets, the company leverages its proprietary platform to advance multiple drug candidates through preclinical and clinical development phases.
Analysis
Management Discussion
Despite a net loss of $80.0M in 2024, the company maintains a healthy liquidity position with $3.9M in cash and equivalents alongside $41.1M in marketable securities. However, the substantial burn rate driven by R&D costs of $46.2M and general administrative expenses of $37.7M underscores the financial pressure on management to secure capital or achieve clinical success soon.
Industry Overview
The neurological therapeutics sector is characterized by high R&D costs and long development timelines, with significant value creation occurring only after regulatory approval. Companies in this space often experience volatile cash flows as they navigate clinical trial phases before generating commercial income.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $161.2M | $103.7M | $83.9M |
| Operating Income | $-161.2M | $-103.7M | $-83.9M |
| R&D | $113.3M | $54.8M | $46.2M |
| G&A | $47.9M | $48.9M | $37.7M |
| Stock-Based Comp | $44.2M | $43.8M | $30.2M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | — | $3.5M |
| Pre-Tax Income | $-161.2M | $-103.7M | $-83.9M |
| Income Tax | $-4.2M | $-4.9M | $-3.9M |
| Continuing Ops | $-157.0M | $-98.8M | $-80.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-157.0M | $-98.8M | $-80.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-157.0M | $-98.8M | $-80.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $152.9M | $97.5M | $45.8M |
| Cash & Equivalents | $5.4M | $4.1M | $3.9M |
| Marketable Securities | $142.9M | $92.2M | $41.1M |
| Other Current Assets | $4.5M | $1.2M | $886.5K |
| Long-Term Assets | $34.9K | $43.1K | $22.0K |
| Total Assets | $152.9M | $97.6M | $45.8M |
| Current Liabilities | $12.5M | $12.2M | $10.3M |
| Accounts Payable | $5.3M | $3.5M | $4.1M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $0 | $0 | $4.5K |
| Total Liabilities | $12.5M | $12.2M | $10.3M |
| Shareholders' Equity | $140.4M | $85.4M | $35.5M |
| Paid-In Capital | $602.5M | $646.2M | $676.4M |
| Retained Earnings | $-462.1M | $-560.9M | $-640.9M |
| Total L&E | $152.9M | $97.6M | $45.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-157.0M | $-98.8M | $-80.0M |
| Non-Cash Adjustments | $56.3M | $50.8M | $30.4M |
| Working Capital Changes | $-3.1M | $-3.6M | $-2.2M |
| Cash from Operations | $-103.8M | $-51.7M | $-51.8M |
| Cash from Investing | $19.7M | $50.5M | $51.6M |
| Cash from Financing | $45.0M | $-98.5K | $-40.3K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-39.0M | $-1.3M | $-234.5K |
| Beginning Cash | $44.4M | $5.4M | $4.1M |
| Ending Cash | $5.4M | $4.1M | $3.9M |
Frequently Asked Questions
How does RELMADA THERAPEUTICS, INC. make money?
The company's financial structure indicates a pure-play biopharmaceutical model with no current revenue-generating segments, relying entirely on research and development (R&D) expenditures of $46.2M to advance its drug portfolio through clinical trials toward potential market launch.
What are the main risks for RLMD?
1. Complete lack of commercial revenue and reliance on external financing given the $640.9M retained earnings deficit. 2. High probability of failure in ongoing or future clinical trials for its drug candidates. 3. Intense competition from established pharmaceutical giants in the neurological disorder space. 4. Potential dilution to existing shareholders if additional equity funding is required to sustain operations.
What is RLMD's competitive advantage?
1. Proprietary molecular glue degrader technology platform targeting specific disease pathways. 2. Experienced management team with a track record of advancing neuroscience candidates from discovery to late-stage development. 3. Significant cash reserves relative to current liabilities, providing operational runway for upcoming clinical milestones.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.